EVQLV

Curated by Signal

Developer of immunotherapies for cancer and immune diseases

Overview

EVQLV develops AI-based immunotherapies for cancer and immune diseases. The pipelines products are CD38 inhibitor for hematologic malignancies, ERBB2 inhibitor for gastroesophageal cancer, and IL17A inhibitor for autoimmune diseases.

Key facts

Founded: 2019
Headquarters: New York City, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

4 products and services: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Geneopedia
Developer of a bioinformatics platform for NGS
Life Sciences TechnologyRochester, United States
Psivant
Developer of therapeutics for cancer and immunology disorders
Life Sciences TechnologyBoston, United States
Lifeline Biotechnologies
Handheld device for early detection of cancer
Life Sciences TechnologyReno, United States

About EVQLV

What does EVQLV do?

EVQLV develops AI-based immunotherapies for cancer and immune diseases.

Where is EVQLV headquartered?

EVQLV is headquartered in New York City, United States.

When was EVQLV founded?

EVQLV was founded in 2019.

Which sector is EVQLV in?

EVQLV operates in Life Sciences Technology.

Who are EVQLV's competitors?

Companies similar to EVQLV include Geneopedia, Psivant, and Lifeline Biotechnologies.